Secondary clinical databases are an important and growing source of data for comparative effectiveness research (CER) studies. However, measurement of confounders, such as biomarker values or patient-reported health status, in secondary clinical databases may not align with the initiation of a new treatment. In many published CER analyses of registry data, investigators assessed confounders based on the first questionnaire in which the new exposure was recorded. However, it is known that adjustment for confounders measured after the start of exposure can lead to biased treatment effect estimates. In the present study, we conducted simulations to compare assessment strategies for a dynamic clinical confounder in a registry-based comparative effectiveness study of 2 therapies. As expected, we found that adjustment for the confounder value at the time of the first questionnaire after the start of exposure creates a biased estimate the total effect of exposure choice on outcome when the confounder mediates part of the effect. However, adjustment for the prior value can also be badly biased when measured long before exposure initiation. Thus, investigators should carefully consider the timing of confounder measurements relative to exposure initiation and the rate of change in the confounder in order to choose the most relevant measure for each patient.
Secondary clinical databases, such as patient registries, electronic health records, and health insurance claims data augmented with biomarker values, are an important and growing source of data for comparative effectiveness research (CER) studies (1) (2) (3) (4) . Secondary clinical data typically contain detailed information on patients' clinical statuses, treatments, and outcomes over long periods of time for routine care. Despite the relative richness of these data, methodological challenges hinder their use in CER. For example, most registries rely on questionnaire data collected at regular intervals. The initiation of a new treatment often occurs between questionnaires, when there may be no information collected on confounders. In many published CER analyses of registry data, investigators assessed confounders on the first questionnaire in which a new exposure was recorded, that is, after initiation of exposure (5) (6) (7) (8) (9) (10) (11) . However, it is known that adjustment for confounders measured after the start of exposure can lead to biased estimates of treatment effect (12) . Similarly, for some patients, a biomarker measurement will prompt a prescription for a new therapy, but for many others, the biomarker of interest may not be measured immediately before start of treatment. In these cases, the optimal approach for assessment of confounders from secondary data remains unclear. The timing of confounder assessment is particularly important for dynamic clinical confounder measures, which can change rapidly over a short period of time compared with more static measures of chronic comorbid conditions.
In the present study, we compared assessment strategies for a dynamic confounder in a comparative effectiveness study of 2 therapies. As our motivating example, we used the comparative risk of infection after exposure to 2 diseasemodifying antirheumatic drugs, abatacept and tocilizumab, in the Brigham Rheumatoid Arthritis Sequential Study (BRASS) registry (13) . In our analysis, the dynamic confounder of interest was the patient global arthritis activity (PGA) scale score. On the basis of this example, we designed synthetic simulation studies to evaluate the performance of confounder measurement strategies with respect to error of the comparative treatment effect estimator under varying data-generating scenarios.
METHODS

Simulation design
In the Brigham Rheumatoid Arthritis Sequential Study, registry questionnaires, which include questions about PGA measurements and data on exposures and infections, are completed approximately every 6 months. The study design utilized in this scenario would identify a cohort of patients initiating abatacept or tocilizumab by identifying the first registry questionnaire in which 1 of these exposures was reported (time T 1 ) and requiring that the prior questionnaire (at time T 0 ) did not list use of that medication. Patients begin exposure (X) to 1 of the 2 drugs under study at some point between the administration of these questionnaires (time T X ); thus, measurement of the confounder, PGA scale score, does not coincide with the beginning of drug exposure for most patients, so C x (the confounder value at exposure start) is unobserved but C 0 and C 1 (the confounder value at T 0 and T 1 ) are available for adjustment. Follow-up for infections (Y) would be assessed from subsequent questionnaires (time T 2 ) in which any infections over the previous interval are reported. Figure 1 depicts the timing and causal relationships among these variables.
Because the postexposure PGA scale score (C 1 ) mediates the causal effect of exposure on outcome, we must define whether the parameter of interest is the total effect, the direct effect, or 1 of several indirect effects (14) . In the example, we are interested in the effect of therapy on the risk of infection, including any effect that is mediated by PGA scale score. Therefore, we focus on estimating the total effect, quantified as the risk ratio, which is given by
is the potential outcome when we set X = x and E denotes expectation. The causal pathways that contribute to this effect are shown with dashed lines in Figure 1 . Web Appendix 1 (available at http://aje.oxfordjournals.org/) provides details of the simulation and parameter values.
Confounder assessment
We compared several potential approaches to confounder assessment. In each case, we adjusted for the confounder of interest through a multivariable logistic regression model for the outcome that included the exposure indicator and the confounder as the independent variables. Alternative methods such as propensity scores could also be used, and results would be expected to be similar (15) . In order to estimate the marginal risk ratio from the logistic regression outcome model, we predicted the risk of outcome under each exposure for each simulated patient and calculated the ratio of the mean risks under the 2 exposure categories.
The confounder assessment approaches that were considered include:
1.
Crude estimate (no adjustment for the confounder; Crude); 2.
Adjustment for the most recent measurement before the start of exposure (C 0 ; Prior); 3.
Adjustment for the nearest measurement after the start of exposure (C 1 ; Post); 4.
Adjustment for the arithmetic mean of the 2 nearest measurements ((C 0 + C 1 )/2; Mean); 5.
Adjustment for the nearest measurement either before or after exposure start (C 0 or C 1 ; Nearest); 6.
Adjustment for a weighted mean of the 2 nearest measurements that accounts for proximity between each measurement and exposure start (
Restriction of the analysis to patients with at least 1 PGA scale measurement within t = 1,2 months before or after exposure start and use of the nearest measurement (C 0 or C 1 ; Nearest, t = 1,2); and 9-13. Restriction of the analysis to patients with at least 1 PGA scale measurement within t = 1 … 5 months before exposure start and use of the prior measurement (C 0 ; Prior, t = 1 … 5)
Approaches 5-13 assume that the timing of exposure start is known, whereas approaches 1-4 do not. Approaches 7-13 restrict the population to those with measurements available in a specific time window, indexed by t.
Sensitivity analyses
For simplicity, we initially simulated data such that questionnaires were received exactly every 6 months and the timing of exposure initiation was uniform across the 6-month period from T 0 to T 1 . We then repeated the simulation, modifying the distribution of exposure initiation times so that most patients initiated shortly after the first questionnaire was administered, as one might expect if patients received a prescription at that time. We also modified the timing of the subsequent questionnaire in which exposure was assessed so that it was variable but centered around 6 months. In the results presented here, the timing of the subsequent questionnaire (T 1 ) did not depend on exposure choice or the confounder value, although in other analyses, changing these parameters did not affect method performance (data not Figure 1 . Timing and causal effects for the simulations. Circles indicate that a registry questionnaire is received at that time. T q is the time of questionnaire q ∈ {0,1,2} and C q is the corresponding confounder value at that time. T X and C X are the time and corresponding confounder value at treatment initiation. X represents treatment choice, and Y indicates outcome.
shown). In each design, we varied the rate of change of the confounder before and after exposure initiation (0.125 and 0.25 standard deviations per month), as well as the magnitude of the relative treatment effect on the confounder. Web Figures 1 and 2 show sample data sets from the 2 simulation designs.
RESULTS
Mean risk ratio estimates with interquartile range intervals from all confounder assessment approaches are shown in Figure 2 . In Figure 2A , data were simulated assuming exposure initiation was uniformly distributed across the 6-month interval between questionnaires. In that simulation, the crude estimate was biased because of confounding. Adjustment for C 0 (Prior) decreased the confounding bias slightly, and adjustment for C 1 (Post) overadjusted it, resulting in unbiased estimation for the null direct effect. Among the approaches that used the full sample, the least biased estimate for the total effect resulted from adjustment for either C 0 or C 1 , depending on which was measured nearest in time (Nearest). Restriction of the sample to patients with a confounder measured within t = 1,2 months either before or after exposure start and adjustment for the nearest confounder measurement (Nearest, t = 1,2) resulted in similar bias but had larger variability because of the reduced sample size. Approaches that restricted the sample to patients with a confounder measured within t months before exposure and were adjusted for C 0 (Prior, t = 1…5) were generally biased for the effect in the full sample but could accurately estimate the effect in the subsample when setting t = 1.
In Figure 2B , exposure initiation occurred soon after the baseline questionnaire for most patients. Thus, adjustment for C 0 (Prior) reduced confounding bias better than it did in the first simulation design. Adjustment for the nearest of either C 0 or C 1 (Nearest) was again less biased for the true total effect, whereas restricting the sample to patients with C 0 measured within 1 month before exposure start was again unbiased for that population, although relatively imprecise. Complete results for all simulation scenarios considered are given in Web Figures 3 and 4 . Results from other scenarios depended on the rate of change of the confounder before and after exposure but generally mirrored the results reported here.
DISCUSSION
In the present study, we examined several approaches for assessing dynamic clinical confounder variables in CER studies created from secondary databases. As expected, we Mean risk ratio (RR) estimates and interquartile ranges for all confounder assessment approaches. A) Data were simulated assuming exposure initiation was uniformly distributed across the 6-month interval between questionnaires. B) Data were simulated assuming exposure initiation occurred soon after the baseline questionnaire for most patients. The true total effect is shown with the solid vertical line; the dashed line marks the true direct effect; and the dotted line marks the true total effect in the population of patients receiving treatment within 1 month after their baseline visit.
found that adjustment for the confounder value measured after exposure start was biased for estimating the total effect of exposure on outcome when the confounder mediated part of the effect. However, we found that adjustment for the most recent prior measurement could also be badly biased when the exposure was sometimes initiated long after the baseline measurement, especially when confounder values changed rapidly before exposure initiation. In that scenario, adjustment for the nearest confounder measurement had better performance, but it could still be biased. Approaches in which we restricted the sample to patients with a confounder measurement within t months before the start of the exposure were generally biased. Bias was expected when we set t = 5 and adjusted for the baseline confounder measurement because this estimator would be similar to using the prior value in the full sample. However, bias was also observed when we set t = 1 because the treatment effect was not homogeneous in the sample. Patients who initiated therapy soon after their baseline confounder measurement exhibited a larger treatment effect because they had been on therapy longer at the time of follow-up. Thus, restricting the sample to this population and adjusting for baseline confounder values provides an approximately unbiased estimator of the effect in this sample, but this may differ substantially from the overall treatment effect in the population of interest.
The results presented here were generally consistent across simulation scenarios within each simulation design, but they varied across designs. Specifically, the performance of adjustment for the baseline confounder value depended on the timing of exposure initiation. We sought to evaluate the performance of assessment approaches under 2 practical distributions for exposure initiation, but other simulation scenarios and designs not explored in this study could have led to different conclusions. Our simulations also focused on the effect of a single continuous-valued confounder that varied over time. If there were several continuous confounders of interest in the data, then all confounders would need to be assessed near exposure initiation. The performance of assessment approaches would also be expected to perform similarly in the case of a binary confounder, although many such variables, such as binary indicators of the presence or absence of comorbid conditions, would be expected to be relatively static over time and therefore less likely to suffer from measurement error in the available data. Finally, in real secondary clinical data, there will be many patients for whom there is no relevant measurement of the confounder of interest or no measurement within a reasonable window around exposure initiation. For these patients, missing-data methods such as multiple imputation may be needed, but these methods were outside the scope of this study.
On the basis of the results from the present study, we recommend that investigators who are designing a CER study should carefully consider the timing of confounder measurement relative to exposure initiation and the expected rate of change in the confounder before and after exposure. To minimize measurement error and bias, confounders should be assessed in close temporal proximity to the start of treatment. Ideally, these measurements should precede exposure initiation; however, measurements taken shortly after exposure initiation may also be useful for confounder adjustment. If the timing of exposure initiation relative to confounder measurements is unknown, all potential approaches can yield badly biased estimates of treatment effect. Restricting the sample to patients who initiate exposure shortly after a confounder measurement is a safe approach, but investigators should be aware of how this restriction affects the target treatment effect parameter. More sophisticated approaches, such as a measurement error model for the confounder at exposure start (16, 17) , were not possible within the simple structure of this simulation, but in real data, such an approach could also be explored to further improve confounding bias.
